June 10, 2013
1 min read
Save

Indices documented similar improvement in patients with rheumatic diseases, osteoarthritis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Two indices and a physician global estimate documented similar baseline and 2-month improvement scores in patients diagnosed with a rheumatic disease or osteoarthritis, according to recent study results.

Researchers studied 141 patients (mean age, 59.2 years; 72% women) diagnosed with osteoarthritis (OA; n=41), rheumatoid arthritis (RA; n=39), systemic lupus erythematosus (SLE; n=14), spondyloarthropathy (SpA; n=23) or gout (n=24). At each visit, patients completed a Multidimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID3; a composite of physical function, pain and patient global estimate [PATGL] measures) and were assigned a physician global estimate (DOCGL).

Patients’ mean and median physical function (FN; 0-10 scale), pain (0-10) and PATGL (0-10), RAPID3 (0-30) and DOCGL (0-10) scores were calculated at baseline and 2-month follow-up. Paired t tests analyzed differences between first visit and at 2 months for all diagnoses. Changes in mean values for each diagnosis also were compared using analysis of variance. Mean baseline scores across all measures showed narrow ranges: FN, 1.5-2.5, pain, 4.2-5.9; PATGL, 4.3-5.6; RAPID3, 10.1-13.7; and DOCGL, 2.4-4.

For all diagnoses except OA (0.6%), FN improvement ranged from 9.4% (gout) to 26.8% (SpA). In all diagnoses, ranges for pain improvement were 20.2% (SpA) to 35.3% (gout); PATGL, 11.3% (SpA) to 30.4% (RA); RAPID3, 16.8% (OA) to 27.5% (RA); and DOCGL, 23.8% (SpA) to 36.4% (OA).

“The data suggest that MDHAQ individual and RAPID3 scores may be informative in a large proportion of patients with many rheumatic diseases,” the researchers concluded. “The narrow range of mean MDHAQ/RAPID3 scores … is similar to the range of baseline and 2-month improvement according to physician global scores, suggesting face validity of the patient self-report data. These quantitative data may supplement traditional narrative, ‘gestalt’ descriptions in usual care of patients with any rheumatic disease.”